Inventprise, Inc.

Pneumococcal Disease Pipeline Shows Strong Growth with 20+ Therapies in Development

- The pneumococcal disease pipeline features over 20 drugs from 18+ companies in various clinical and preclinical stages, addressing a significant global health threat. - Sanofi's PCV21, a 21-valent pneumococcal conjugate vaccine in Phase III, leads the late-stage pipeline targeting both pediatric and adult populations worldwide. - Vaxcyte's VAX-31 received FDA Breakthrough Therapy designation and showed strong immune responses in Phase I/II trials involving 1,015 adults aged 50 and older. - The market is driven by high global disease burden, rising antimicrobial resistance, and expanded immunization initiatives, particularly in developing regions.